Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Updated study results show antibody-drug conjugate plus Keytruda shrinks tumors in 73% of patients.
Immunotherapy may prolong survival compared with standard chemotherapy.
In a clinical trial, 46% of responding participants experienced a complete response lasting at least 12 months.
Keytruda improves response rates for hard-to-treat breast cancer, but Tecentriq falls short.
New site-agnostic therapies highlight the importance of genetic testing.
Longer-term follow-up shows improved overall survival with Keytruda or Opdivo.
The investigational machine has an 85% accuracy rate.
Enfortumab vedotin plus Keytruda yielded a confirmed response in 71% of participants.
Adding immunotherapy to preoperative chemotherapy increased the likelihood of complete remission.
Keytruda plus Lenvima is first approval under Project Orbis collaboration.
Biomarker was not linked to response rates in two studies of Keytruda for lung cancer.
pembrolizumab’s efficacy was investigated in two clinical trials of people with recurrent, locally advanced or metastatic disease.
As an eligibility barrier cracks, a lung cancer patient gets a new lease on life.
New immunotherapy option approved for uncommon, aggressive type of lung cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.